KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Short-Term Debt repayments (2016 - 2025)

Pfizer (PFE) has disclosed Short-Term Debt repayments for 13 consecutive years, with $151.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Short-Term Debt repayments fell 96.66% to $151.0 million in Q2 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 80.41% decrease, with the full-year FY2025 number at $2.2 billion, down 80.41% from a year prior.
  • Short-Term Debt repayments was $151.0 million for Q2 2025 at Pfizer, down from $2.0 billion in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $4.5 billion in Q2 2024 to a low of $1.0 million in Q4 2021.
  • A 5-year average of $1.9 billion and a median of $2.0 billion in 2025 define the central range for Short-Term Debt repayments.
  • Peak YoY movement for Short-Term Debt repayments: plummeted 99.99% in 2021, then surged 388600.0% in 2022.
  • Pfizer's Short-Term Debt repayments stood at $1.0 million in 2021, then soared by 388600.0% to $3.9 billion in 2022, then tumbled by 99.92% to $3.0 million in 2023, then surged by 114966.67% to $3.5 billion in 2024, then crashed by 95.63% to $151.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Short-Term Debt repayments are $151.0 million (Q2 2025), $2.0 billion (Q1 2025), and $3.5 billion (Q4 2024).